Lexeo Therapeutics, Inc.
LXEO Healthcare Biotechnology
Lexeo Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $654,000.00. In the quarter to June 2026, EPS grew 50.0%, free cash flow grew 35.6% and total debt fell 83.5%, each against the same quarter a year earlier.
Follow LXEO
Lexeo Therapeutics, Inc. (LXEO) Beneish M-score
Lexeo Therapeutics, Inc.'s Beneish M-score for fiscal 2022 cannot be worked out: days’ sales in receivables index cannot be worked out.
Beneish M-score, annual
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|
How fiscal 2022’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | — | — | n/a | — |
| Gross margin index | 0.99 | — | 0.52 | |
| Asset quality index | 9,039.84 | — | 3652.10 | |
| Sales growth index | 0.39 | — | 0.35 | |
| Depreciation index | 0.67 | — | 0.08 | |
| SG&A index | 4.25 | — | −0.73 | |
| Total accruals to total assets | (0.05) | — | −0.23 | |
| Leverage index | 3.03 | — | −0.99 | |
| Beneish M-score | n/a — days’ sales in receivables index cannot be worked out | — | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| IMRX Immuneering Corporation compare | −6.3× |
| FATE Fate Therapeutics, Inc. compare | −4.0× |
| SLGL Sol-Gel Technologies Ltd. compare | −3.6× |
| PLX Protalix BioTherapeutics, Inc. compare | −0.1× |
| KROS Keros Therapeutics, Inc. compare | 57.0× |
| GLSI Greenwich LifeSciences, Inc. compare | — |
| SABS SAB Biotherapeutics, Inc. compare | — |
| QTTB Q32 Bio Inc. compare | — |
| LXEO Lexeo Therapeutics, Inc. | — |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI